A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer.

导出 LinkOut

翻译打印收藏纠错

作者： Bogang,Wu ^[1] ; Win,Thant ^[1] ; Elena,Bitman ^[1] ; Ting,Liu ^[1] ; Jie,Liu ^[2] ; Eleftherios I,Paschalis ^[2] ; Katherine H,Xu ^[1] ; Linda T,Nieman ^[1] ; David T,Ting ^[1] ; Nayana,Thimmiah ^[1] ; Sheng,Sun ^[1] ; Rachel O,Abelman ^[1] ; Steven J,Isakoff ^[1] ; Laura M,Spring ^[1] ; Aditya,Bardia ^[1] ; Leif W,Ellisen ^[3]

作者单位： Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA. ^[1] Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, 02114, USA. ^[2] Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.;Ludwig Center at Harvard, Boston, MA 02115, USA. ^[3]

关键词 Antibody-Drug Conjugate PD-1 TROP2 antitumor immunity immune checkpoint blockade immune exclusion sacituzumab govitecan tight junction triple negative breast cancer tumor immune microenvironment

DOI 10.1101/2024.12.02.626446

PMID 39677819

发布时间 2025-01-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

bioRxiv

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer.

bioRxiv

相似文献

bioRxiv

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer.

bioRxiv

相似文献

bioRxiv

相关期刊

检索历史清除